Mycardioguard

Our mission is to significantly reduce the devastating effects of cardiovascular disease in the United States and around the World through the proliferation of our FDA approved myCardioGuard® Heart ScreenTM which accurately, safely, inexpensively, and in 15 minutes detects early-stage CVD in individuals with few or no symptoms. Existing approaches to early detection and prevention are insufficiently predictive and effective. As a result, cardiovascular disease is still today:#1 Cause of Death in the World #1 Most Costly Disease in World major risk factor for patients with COVID-19 We are the solution. Our strategy is to attack cardiovascular disease (CVD) by expanding the use of its unique screening processes that can detect early stages of heart disease that occurs before plaque formation. This provides opportunity for early intervention and treatment and thus prevention. For individuals diagnosed with early-stage heart disease, starting treatment can halt progression of the disease and potentially reverse the pathologic effects of early CVD before its devastating natural advancement to a heart attack or stroke. The technology and myCardioGuard® protocol provide primary care physicians and cardiologists with the screening framework to identify and analyze the predictive diagnostic markers required to provide care and formulate treatment plans